Wayne State University Division of Research

Wayne State University team receives $1.98 million NIH award to develop diagnostic tests for sarcoidosis

Newswise — DETROIT – Sarcoidosis is an inflammatory disease of unknown causes that affects multiple organs in the body. It occurs in patients around the world and is highly prevalent in Detroit and Michigan. It is characterized by abnormal masses or nodules – granuloma formations – in various organs, including lungs and lymph glands, brains and heart. Sarcoidosis has been described for more than 150 years, but there are no specific and simple tests developed to diagnose this disease.

Currently, sarcoidosis is diagnosed through confirmation of non-caseating granulomas in tissue biopsies of organs where there is no other applicable diagnosis. Sarcoidosis is similar to tuberculosis, which is an infectious granulomatous disease. Active tuberculosis infection can be deadly. Exposure to bacterial tuberculosis may stay dormant for long time and is called latent tuberculosis. One third of humans worldwide are infected with latent tuberculosis but have no symptoms. Under specific circumstances, such as immune suppression, these individuals may develop full-blown tuberculosis. There are no simple tests to discover latent tuberculosis infection from tuberculosis disease or from sarcoidosis. 

A team of researchers led by Lobelia Samavati, M.D., associate professor in the Center for Molecular Medicine and Genetics and Department of Internal Medicine at Wayne State University’s School of Medicine, has been working for more than 10 years to discover specific serological biomarkers of sarcoidosis and tuberculosis.

With the help of a recent $1.98-million grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health, Samavati’s research team aims to advance their work of developing biomarker technology for identification of biomarkers of sarcoidosis.  

Samavati developed a comprehensive library derived from sarcoidosis tissue that can differentiate between sarcoidosis and several other respiratory disorders. Using a high throughput method, her team developed a complex epitope library derived from materials of sarcoidosis patients. This cDNA library contains large numbers of epitopes immunoscreened with sera from patients with sarcoidosis containing high titer IgG antibodies and the cloned phages, which have been used to construct an antigen microarray to detect antibodies against sarcoid antigen(s) in the sera of test subjects.

“We have identified a panel of biomarkers/classifiers with high sensitivity and specificity that can discriminate between sera of patients with sarcoidosis and healthy controls, as well as active tuberculosis subjects,” said Samavati. “Our results have been published in several peer-reviewed journals, and we have two different licenses for our invention.”

Samavati’s grant, “A Novel T7 Phage Display Technology to Detect Sarcoidosis Specific Antigens,” aims to advance and refine her technology to discriminate sarcoidosis from latent tuberculosis and healthy controls. Her team has identified novel antibodies that may be used as a molecular therapy target, and their goal over the next four years is to further map these peptides and identify their biological function. Their current data indicates that some of these peptides can be used as diagnostic tools, while others can be used as therapy targets.

The overall goal is to define the specific antigens initiating granuloma formation in sarcoidosis and how immunity in response to antigen leads to sarcoidosis and latent tuberculosis. In the future, this approach could be used to identify a panel of biomarkers useful for diagnosis of various organ involvements in sarcoidosis and differential diagnosis of other granulomatous diseases or response to treatment in sarcoidosis subjects. Furthermore, the identified antigens can be used to develop a model for sarcoidosis.

Using a high-throughput method, Samavati and her research team developed a novel platform based on T7 phage library — a cDNA library derived from mRNA isolated from bronchoalveolar lavage (BAL) and leucocytes of sarcoidosis patients. They constructed a microarray platform and immunoscreened with sarcoidosis subjects, tuberculosis, healthy controls and other respiratory diseases.

The phage display technology and immunoscreening have utilities not only in identification of diagnostic biomarkers, but also may enable Samavati and others to develop a novel targeted therapy utilizing the peptide sequences (mimotopes) as a vehicle to deliver specific drugs.

“We believe that our technology will be able to harness the diversity of antibodies and can aid to identify protective antibodies in various diseases in humans, including viral respiratory infections such as the corona virus,” said Samavati. “We believe that this study is the beginning of new era to identify protective immunity in form of antibodies.

Sorin Draghici, the Robert J. Sokol, M.D. Endowed Chair in Systems Biology in Reproduction and professor of computer science in Wayne State’s College of Engineering, is collaborating with Samavati. He contributed to the design of the study and will supervise the data analysis.

The grant number for this National Institutes of Health project is HL150474.

# # #

Wayne State University is one of the nation’s pre-eminent public research institutions in an urban setting. Through its multidisciplinary approach to research and education, and its ongoing collaboration with government, industry and other institutions, the university seeks to enhance economic growth and improve the quality of life in the city of Detroit, the state of Michigan and throughout the world. For more information about research at Wayne State University, visit http://www.research.wayne.edu.




Filters close

Showing results

110 of 5640
Released: 15-May-2021 8:05 AM EDT
Rutgers Reports First Instance of COVID-19 Triggering Recurrent Blood Clots in Arms
Rutgers University-New Brunswick

Researchers at Rutgers Robert Wood Johnson Medical School are reporting the first instance of COVID-19 triggering a rare recurrence of potentially serious blood clots in people’s arms.

access_time Embargo lifts in 2 days
Embargo will expire: 20-May-2021 10:00 AM EDT Released to reporters: 14-May-2021 2:40 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 20-May-2021 10:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 14-May-2021 11:25 AM EDT
Access to overdose-reversing drugs declined during pandemic, researchers find
Beth Israel Lahey Health

In a new study, clinician-researchers at Beth Israel Deaconess Medical Center (BIDMC) analyzed naloxone prescription trends during the COVID-19 pandemic in the United States and compared them to trends in opioid prescriptions and to overall prescriptions.

Released: 14-May-2021 11:00 AM EDT
No Excuses: Stop Procrastinating on These Key Health Checks
Michigan Medicine - University of Michigan

A quick guide to the most-valuable preventive care that adults need to get scheduled, to catch up on what they may have missed during the height of the pandemic, and to address issues that the pandemic might have worsened.

Released: 13-May-2021 7:05 PM EDT
FLCCC Statement on the Irregular Actions of Public Health Agencies & the Disinformation Campaign Against Ivermectin
Front Line COVID-19 Critical Care Alliance (FLCCC Alliance)

FLCCC Alliance calls for whistleblower to step forward from within WHO, the FDA, the NIH, Merck, or Unitaid to counter this misrepresentation

Newswise: shutterstock_1724336896.jpg
Released: 13-May-2021 12:55 PM EDT
Kreuter receives $1.9 million in grants to increase vaccinations in St. Louis
Washington University in St. Louis

Matthew Kreuter, the Kahn Family Professor of Public Health at the Brown School, has received $1.9 million in grants to help increase COVID-19 vaccinations among Blacks in St. Louis City and County.

Released: 13-May-2021 11:35 AM EDT
COVID-19 mRNA Vaccines are Immunogenic in Pregnant and Lactating Women, Including Against Viral Variants
Beth Israel Deaconess Medical Center

In a new study from Beth Israel Deaconess Medical Center researchers evaluated the immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women who received either the Pfizer or Moderna COVID-19 vaccines. They found that both vaccines triggered immune responses in pregnant and lactating women.

Released: 13-May-2021 10:30 AM EDT
Pandemic stigma: Foreigners, doctors wrongly targeted for COVID-19 spread in India
Monash University

The Indian public blamed foreigners, minority groups and doctors for the rapid spread of COVID-19 across the country during the first wave, due to misinformation, rumour and long-held discriminatory beliefs, according to an international study led by Monash University.


Showing results

110 of 5640

close
2.0573